SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, ...

Seongnam: SK bioscience, a global vaccine and biotech company, has announced that the Supreme Court of Korea has ruled in its ...

Some five years into a pneumococcal vaccine patent dispute in South Korea, SK Bioscience has emerged victorious over Pfizer.

SK bioscience successfully developed Korea's first 13-valent pneumococcal conjugate vaccine, SKYPneumo, in 2016. However, due to the ongoing patent dispute with Pfizer, the company has been ...

South Korean vaccine maker SK Bioscience has secured a final court victory over US pharma major Pfizer in a long-running ...

South Korean vaccine company SK Bioscience said it has prevailed in a lawsuit brought by Pfizer that accused it of infringing on the patent for the drugmaker's Prevnar 13 vaccine.

SEOUL, May 21 (Yonhap) -- SK bioscience Co., a biotech arm of South Korea's SK Group, said Wednesday it has won a patent ...

The introduction of the heptavalent pneumococcal conjugate vaccine (PCV7) in the U.S. in 2000 was a welcome addition to our preventive armamentarium; however, questions remain regarding the degree ...

Antimicrobial resistance and serotypes in Streptococcus pneumoniae have been evolving with the widespread use of antibiotics and the introduction of pneumococcal conjugate vaccines (PCV).